bioAffinity Technologies, Inc. Common Stock (BIAF) is a publicly traded Healthcare sector company. As of May 21, 2026, BIAF trades at $1.66 with a market cap of $7.64M and a P/E ratio of -0.24. BIAF moved -2.94% today. Year to date, BIAF is +32.80%; over the trailing twelve months it is -81.06%. Its 52-week range spans $0.69 to $67.12. Rallies surfaces BIAF's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
bioAffinity Case Study: 92% Sensitive CyPath Lung Test Spares 71-Year-Old Biopsy: bioAffinity Technologies published a case study on a 71-year-old former heavy smoker whose 7mm pulmonary nodule yielded a negative CyPath® Lung result, enabling a three-month follow-up CT instead of invasive biopsy. The subsequent scan showed nodule resolution, underscoring the test’s reported 92% sensitivity, 87% specificity and potential cost savings.
| Metric | Value |
|---|---|
| Price | $1.66 |
| Market Cap | $7.64M |
| P/E Ratio | -0.24 |
| EPS | $-6.83 |
| Dividend Yield | 0.00% |
| 52-Week High | $67.12 |
| 52-Week Low | $0.69 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $5.66M |
| Net Income | $-15.88M |
| Gross Margin | 0.00% |
BIAF analyst coverage data. Average price target: $0.00.